# **Emkay**

# Research

3 May 2007

### **BUY**

Price Target Price Rs 1,035 Rs 1,150

Sensex - 14,209

#### **Price Performance**

| (%)            | 1 M | 3M | 6M  | 12M |
|----------------|-----|----|-----|-----|
| Absolute       | 13  | 14 | 118 | 161 |
| Rel. to Sensex | 1   | 14 | 103 | 128 |

Source: Bloomberg

#### **Stock Details**

| Sector                         | IT Services |
|--------------------------------|-------------|
| Reuters                        | NESL.BO     |
| Bloomberg                      | NCS@IN      |
| Equity Capital (Rs mn)         | 161         |
| Mkt. Cap (Rs bn)               | 16.7        |
| Face Value (Rs)                | 10          |
| 52 Week H/L R                  | s 1,199/245 |
| Daily Avg Volume (No of shares | 66955       |
| Daily Avg Turnover (US\$ mn)   | 1.6         |

#### **Shareholding Pattern (%)**

| Promoters    | 59.8 |
|--------------|------|
| FIIs /NRI's  | 6.6  |
| Institutions | 8.1  |
| Private Corp | 6.7  |
| Public       | 18.9 |

Source: BSE,31.Mar.2007

#### Krupal Maniar, CFA

krupal.maniar@emkayshare.com

91-22-66121253

# **Nucleus Software Exports Ltd.**

## Strong business momentum

#### Q4 below expectations

Nucleus Software posted revenue growth of 7.1% qoq to Rs 602 mn on the back of strong growth in products (12.3% qoq). Products revenues now contribute ~60% of total revenues during Q4FY07, up from 38% in FY06. EBITDA margins improved by 60 bps qoq to 28.5% due to lower software development expenses, despite one-time expenses to the tune of Rs 18 mn on account of penalty for delay in execution of the project. EBITDA jumped by 9.5% to Rs 172 mn. However, due to lower other income and higher depreciation and taxes, PAT was flat at Rs 139 mn, below our expectations of Rs 155 mn.

#### **Key Highlights for FY07**

- Order book position stood at Rs 3.3 bn, Rs 2.86 bn pertaining to products and balance services. Rs 1.56 bn products order book to be executed in a year time.
- Orders spread includes from India, Sri Lanka, UAE, Nigeria, Japan & Singapore.
- 21 new clients added, taking total active clients to 141.
- 22 new product orders won for implementing 74 modules of FinnOne suite and other products.
- FinnOne suite ranked as the No 1 best selling retail lending software by IBS Publishing, London.
- FinnOne lending now covers almost 75% of the Retail Business in India.
- Multi country roll outs for FinnOne and Cash@Will suite.
- Won a multi million dollar (~ US\$ 35 mn) deal from ACOM Corporation, Japan.
- Leading banks in Japan / Middle East/ Africa /Sri Lanka and India chose Nucleus Software FinnOne.
- Bagged multi country deals from leading banks in SAARC & SEA region for Cash@Will suite.
- Commissioned the second facility block at the existing campus in Noida with the proposed investment of Rs 200 mn, which will seat 800+ additional personnel.
- Added 464 employees in the year, taking total head count to 1532.
- 'Cash and Bank Balances' and 'Current Investments' were at Rs 819 mn as on March 31, 2007.

#### **Key Financials (Rsmn)**

| Mar   | Rev  | EBITDA | EBITDA | PAT  | EPS  | RoE  | EV/    | P/BV | Div Yld | P/E  |
|-------|------|--------|--------|------|------|------|--------|------|---------|------|
|       |      |        | (%)    |      | (Rs) | (%)  | EBITDA | (x)  | (%)     | (x)  |
| FY06  | 1481 | 451    | 30.4   | 371  | 23.0 | 32.1 | 37.0   | 14.5 | 0.3     | 45.0 |
| FY07  | 2212 | 632    | 28.6   | 552  | 33.9 | 33.2 | 26.5   | 10.5 | 0.3     | 30.6 |
| FY08E | 3319 | 992    | 29.9   | 857  | 51.0 | 35.1 | 16.9   | 7.2  | 0.4     | 20.3 |
| FY09E | 4705 | 1383   | 29.4   | 1205 | 71.7 | 33.8 | 12.1   | 4.9  | 0.4     | 14.4 |

Source: Company, Emkay research

#### Strong FY07 results

Nucleus Software posted revenue growth of 49% yoy to Rs 2,212 mn on the back of strong growth in products revenues (111% yoy). Products revenues now contribute 54% of total revenues during FY07, up from 38% in FY06. EBITDA margins declined by 180 bps to 28.6% mainly due to higher employee costs. However, due to higher other income and lower taxes (effective tax rate reduced from 14.6% to 11.1%), PAT grew by 49% yoy to Rs 552 mn. FDEPS stood at Rs 33.85. The company declared bonus in the ratio of 1:1.

#### Continuance investments in new product development and upgrades

The company is continuously investing in new product development and upgrading the existing products suite. The company continues with their focus on 'SME Loan Origination and Servicing' business domain. FinnOne Collections product, which concentrates on debt collections and delinquency management business, was upgraded in Q3FY07 functionally to cater to the new requirements for retail lending and credit card business. The new version would focus more on improving management reporting in order to ensure tight control on delinquency. New product module, FinnForecaster, a Java-based interactive suite that transforms organizational data to business solution is expected to be launched in the current financial year. Cash@will would be upgraded with Electronic Bill Presentation, RTGS and other two modules. This product made significant inroads in India, Malaysia and Singapore during FY07. We believe the company is continuously investing in new product development and upgrades, which augurs well for the sustainable future growth of the company.

#### Risks and concerns

We believe attracting and retaining the right talent is the biggest challenge for the company. The company had announced wage hike twice a year during FY07. The company expects wage hike of 15-18% for FY08E. Attrition at 19% can have huge adverse impact on a mid-size company like Nucleus Software. We believe the company's retention initiatives could impact margins of the company.

#### **Future Outlook and Valuations**

We believe Nucleus Software would continue to maintain its leadership in Retail Lending segments globally. Nucleus Software has successfully maintained the highest level of global worldwide partnerships with technology giants like HP, IBM, Intel & Oracle. We have revised our estimates for FY08E to take into consideration recent rupee appreciation and introduced FY09E. We now expect Nucleus Software to post 46% CAGR in revenues and 48% CAGR in profits for FY07-09E. We expect fully diluted EPS of Rs 51.0 for FY08E and Rs 71.7 for FY09E based on 16.8 mn equity shares. At CMP of Rs 1,035, it trades at a P/E of 20.3x and 14.4x and EV/EBITDA of 16.9x and 12.1x based on FY08E and FY09E respectively. With EBITDA margin of 30%, PAT margin of 25-26%, ROE of 35%, PEG of 0.4 for FY08E and strong visibility of future growth, we believe Nucleus Software is an attractive investment proposition. We maintain BUY with a revised one year price target of Rs 1,150 (16x FY09E).

Emkay Research 3 May, 2007 2

## **Q4FY07 Results Analysis**

| Consolidated (Rs mn)     | Dec-06 | Mar-07 |
|--------------------------|--------|--------|
| Total Revenue            | 562    | 602    |
| Growth (%) q-o-q         | 2.0    | 7.1    |
| Product Revenue          | 318    | 357    |
| Growth (%) q-o-q         | 12.8   | 12.3   |
| Project Revenue          | 205    | 234    |
| Growth (%) q-o-q         | (10.9) | 14.0   |
| Professional Services    | 39     | 11     |
| Growth (%) q-o-q         | 0.1    | (71.4) |
| Software Development Exp | 317    | 322    |
| Gross Profit             | 245    | 280    |
| Selling & Marketing Exp  | 55     | 52     |
| General & Admin Exp      | 33     | 56     |
| EBIDTA                   | 157    | 172    |
| Growth (%) q-o-q         | (2.0)  | 9.5    |
| EBIDTA (%)               | 27.9   | 28.5   |
| Add: Other Income        | 16     | 8      |
| Less: Depreciation       | 17     | 21     |
| PBT                      | 156    | 159    |
| Less: Tax                | 16     | 20     |
| PAT                      | 139    | 139    |
| Growth (%) q-o-q         | -      | -      |
| PAT (%)                  | 24.8   | 23.2   |
| EPS                      | 8.7    | 8.7    |

Source: Company

Emkay Research 3 May, 2007 3

| Profit & Loss Statement   |       |       |       |       |
|---------------------------|-------|-------|-------|-------|
| Mar end (Rs mn)           | FY06  | FY07  | FY08E | FY09E |
| Product revenues          | 568   | 1,198 | 2,168 | 3,411 |
| Growth (%)                | 115   | 111   | 81    | 57    |
| Projects revenues         | 782   | 885   | 1,058 | 1,194 |
| Growth (%)                | 14    | 13    | 19    | 13    |
| Professional services     | 131   | 129   | 92    | 100   |
| Growth (%)                | 60    | (1)   | (28)  | 8     |
| Total Revenues            | 1,481 | 2,212 | 3,319 | 4,705 |
| Growth (%)                | 43.5  | 49.4  | 50.0  | 41.8  |
| Software Development Cost | 805   | 1,251 | 1,838 | 2,639 |
| Selling & Marketing Exp.  | 117   | 179   | 276   | 385   |
| General & Admin. Expenses | 108   | 149   | 212   | 297   |
| EBITDA                    | 451   | 632   | 992   | 1,383 |
| Growth (%)                | 66.4  | 40.4  | 56.9  | 39.4  |
| EBITDA margin (%)         | 30.4  | 28.6  | 29.9  | 29.4  |
| Other Income              | 31    | 57    | 68    | 100   |
| Depreciation              | 48    | 69    | 100   | 137   |
| PBT                       | 434   | 620   | 959   | 1,347 |
| Tax                       | 64    | 69    | 103   | 142   |
| PAT                       | 371   | 552   | 857   | 1,205 |
| Growth (%)                | 78.7  | 48.7  | 55.3  | 40.7  |
| PAT margin (%)            | 25.0  | 24.9  | 25.8  | 25.6  |

Source : Company, Emkay Research

| Balance Sheet              |       |       |       |       |
|----------------------------|-------|-------|-------|-------|
| Mar end (Rs mn)            | FY06  | FY07  | FY08E | FY09E |
| Equity Capital             | 161   | 162   | 162   | 162   |
| Share Application Money    | 1     | 7     | 7     | 7     |
| Reserves                   | 994   | 1,490 | 2,270 | 3,398 |
| Networth                   | 1,156 | 1,659 | 2,438 | 3,567 |
| Deferred Tax Liability     | -     | 3     | 3     | 3     |
| Total Capital Employed     | 1,156 | 1,662 | 2,442 | 3,570 |
| Gross Block                | 501   | 685   | 1,035 | 1,385 |
| Less Depreciation          | 202   | 266   | 366   | 503   |
| Net Fixed Assets           | 300   | 420   | 669   | 883   |
| CWIP                       | 38    | 131   | 100   | 125   |
| Investments                | 614   | 690   | 850   | 1,000 |
| Debtors                    | 238   | 553   | 682   | 967   |
| Cash and Bank              | 300   | 268   | 954   | 1,748 |
| Loans & Advances           | 76    | 95    | 133   | 188   |
| Other Current Assets       | 38    | 182   | 100   | 141   |
| Total Curr. Assets         | 653   | 1,097 | 1,868 | 3,044 |
| Current Liabilites         | 354   | 625   | 830   | 1,176 |
| Provisions                 | 94    | 51    | 216   | 306   |
| Total Curr. Liabi. & Prov. | 448   | 676   | 1,045 | 1,482 |
| Net Current Assets         | 205   | 421   | 822   | 1,562 |
| Total Assets               | 1,156 | 1,662 | 2,442 | 3,570 |

Source : Company, Emkay Research

| Cash Flow                     |         |       |       |       |
|-------------------------------|---------|-------|-------|-------|
| Mar end (Rs mn)               | FY06    | FY07  | FY08E | FY09E |
| Profit Before Tax             | 434     | 620   | 959   | 1,347 |
| Depreciation                  | 48      | 69    | 100   | 137   |
| Operating C F                 | 482     | 689   | 1,060 | 1,484 |
| Change in working capital     | (125)   | (248) | 272   | 55    |
| Less:Direct Taxes             | (54)    | (69)  | (103) | (142) |
| C F from Operating            | 303     | 372   | 1,229 | 1,396 |
| C F from Investing            |         |       |       |       |
| (Purchase)/Sale of Fixed Asse | et (96) | (277) | (319) | (375) |
| (Purchase)/Sale of Investment | (127)   | (76)  | (160) | (150) |
| Others                        | -       | 14    | -     | -     |
| Net C F from Investing        | (223)   | (340) | (479) | (525) |
| C F from Financing            | -       | -     | -     | -     |
| Dividend Paid                 | (46)    | (64)  | (64)  | (77)  |
| Net C F from Financing        | (46)    | (64)  | (64)  | (77)  |
| Net Increase/(Decrease)       | 34      | (32)  | 685   | 795   |
| Opening Balance               | 266     | 300   | 268   | 954   |
| Closing Balance               | 300     | 268   | 954   | 1,748 |

Source : Company, Emkay Research

| Ratios               |      |      |       |       |
|----------------------|------|------|-------|-------|
| Mar end              | FY06 | FY07 | FY08E | FY09E |
| EBITDA margin        | 30.4 | 28.6 | 29.9  | 29.4  |
| PAT margin           | 25.0 | 24.9 | 25.8  | 25.6  |
| ROCE                 | 37.6 | 37.3 | 39.3  | 37.7  |
| ROE                  | 32.1 | 33.2 | 35.1  | 33.8  |
| Per Share Data (Rs.) |      |      |       |       |
| EPS                  | 23.0 | 33.9 | 51.0  | 71.7  |
| CEPS                 | 26.1 | 38.5 | 57.0  | 79.9  |
| BVPS                 | 71.4 | 98.3 | 144.5 | 211.3 |
| DPS                  | 3.5  | 3.5  | 4.0   | 4.0   |
| Valuation (x)        |      |      |       |       |
| P/E                  | 45.0 | 30.6 | 20.3  | 14.4  |
| Cash PE              | 39.7 | 26.9 | 18.2  | 13.0  |
| P/BV                 | 14.5 | 10.5 | 7.2   | 4.9   |
| EV/EBITDA            | 37.0 | 26.5 | 16.9  | 12.1  |
| EV/Sales             | 11.3 | 7.6  | 5.0   | 3.6   |
| PEG                  | 0.6  | 0.6  | 0.4   | 0.4   |
| Dividend Yield %     | 0.3  | 0.3  | 0.4   | 0.4   |

Source : Company, Emkay Research

Emkay Research 3 May, 2007